Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 18/20 | 0.50 |
| ▸ | THRA | P10827 | 17/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927372 | 0.91 | THRB (0.52) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4929364 | 0.90 | FABP4 (0.42) | THRBTHRASMN1; SMN2FABP4FABP5 | |
| SCHEMBL4922958 | 0.90 | THRA (0.60) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4930994 | 0.89 | THRB (0.51) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4933354 | 0.88 | THRB (0.49) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL5118008 | 0.85 | THRB (0.53) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL5103564 | 0.85 | THRB (0.49) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4927363 | 0.84 | THRB (0.49) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4931330 | 0.84 | SMN1; SMN2 (0.39) | THRBTHRASMN1; SMN2 | |
| SCHEMBL5112714 | 0.83 | THRB (0.55) | THRBTHRAESR1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | KARO BIO AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1732533-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092317-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | TSHR, TRHR, THRA | THRB 4/4885THRA 3/4885ESR1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.